Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents

Joshua Wolf, Mark J. Abzug, Brenda I. Anosike, Surabhi B. Vora, Alpana Waghmare, Paul K. Sue, Rosemary M. Olivero, Carlos R. Oliveira, Scott H. James, Theodore H. Morton, Gabriela M. Maron, Jennifer L. Young, Rachel C. Orscheln, Hayden T. Schwenk, Laura L. Bio, Zachary I. Willis, Elizabeth C. Lloyd, Adam L. Hersh, Charles W. Huskins, Vijaya L. SomaAdam J. Ratner, Molly Hayes, Kevin Downes, Kathleen Chiotos, Steven P. Grapentine, Rachel L. Wattier, Gabriella S. Lamb, Philip Zachariah, Mari M. Nakamura

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Starting in November 2020, the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing monoclonal antibody therapies, including bamlanivimab monotherapy (now revoked), bamlanivimab and etesivimab, casirivimab and imdevimab (REGEN-COV), and sotrovimab, for treatment or postexposure prophylaxis of Coronavirus disease 2019 (COVID-19) in adolescents (≥12 years of age) and adults with certain high-risk conditions. Previous guidance is now updated based on new evidence and clinical experience. Methods: A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacotherapy, and pediatric critical care medicine from 18 geographically diverse US institutions was convened. Through a series of teleconferences and web-based surveys, a guidance statement was developed and refined based on a review of the best available evidence and expert opinion. Results: The course of COVID-19 in children and adolescents is typically mild, though more severe disease is occasionally observed. Evidence supporting risk stratification is incomplete. Randomized controlled trials have demonstrated the benefit of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific monoclonal antibody therapies in adults, but data on safety and efficacy in children or adolescents are limited. Potential harms associated with infusion reactions or anaphylaxis are reportedly low in adults. Conclusions: Based on evidence available as of August 31, 2021, the panel suggests a risk-based approach to administration of SARS-CoV-2 monoclonal antibody therapy. Therapy is suggested for the treatment of mild to moderate COVID-19 in adolescents (≥12 years of age) at the highest risk of progression to hospitalization or severe disease. Therapeutic decision-making about those at moderate risk of severe disease should be individualized. Use as postexposure prophylaxis could be considered for those at the highest risk who have a high-risk exposure but are not yet diagnosed with COVID-19. Clinicians and health systems should ensure safe and timely implementation of these therapeutics that does not exacerbate existing healthcare disparities.

Original languageEnglish (US)
Pages (from-to)177-185
Number of pages9
JournalJournal of the Pediatric Infectious Diseases Society
Volume11
Issue number5
DOIs
StatePublished - May 1 2022

Keywords

  • bamlanivimab and etesevimab
  • COVID-19
  • pediatric
  • REGEN-COV (casirivimab and imdevimab)
  • sotrovimab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents'. Together they form a unique fingerprint.

Cite this